Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1124.02
GLPGF's Cash to Debt is ranked higher than
56% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. GLPGF: 1124.02 )
Ranked among companies with meaningful Cash to Debt only.
GLPGF' s 10-Year Cash to Debt Range
Min: 2.96  Med: 32.45 Max: No Debt
Current: 1124.02
Equity to Asset 0.76
GLPGF's Equity to Asset is ranked higher than
58% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GLPGF: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
GLPGF' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.71 Max: 0.77
Current: 0.76
0.5
0.77
F-Score: 4
Z-Score: 14.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -52.80
GLPGF's Operating margin (%) is ranked higher than
53% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. GLPGF: -52.80 )
Ranked among companies with meaningful Operating margin (%) only.
GLPGF' s 10-Year Operating margin (%) Range
Min: -59.16  Med: -33.12 Max: 1.78
Current: -52.8
-59.16
1.78
Net-margin (%) 47.88
GLPGF's Net-margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. GLPGF: 47.88 )
Ranked among companies with meaningful Net-margin (%) only.
GLPGF' s 10-Year Net-margin (%) Range
Min: -58.19  Med: -19.95 Max: 47.88
Current: 47.88
-58.19
47.88
ROE (%) 16.65
GLPGF's ROE (%) is ranked higher than
90% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. GLPGF: 16.65 )
Ranked among companies with meaningful ROE (%) only.
GLPGF' s 10-Year ROE (%) Range
Min: -24.8  Med: -9.47 Max: 17.79
Current: 16.65
-24.8
17.79
ROA (%) 11.55
GLPGF's ROA (%) is ranked higher than
91% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. GLPGF: 11.55 )
Ranked among companies with meaningful ROA (%) only.
GLPGF' s 10-Year ROA (%) Range
Min: -18.65  Med: -6.10 Max: 11.91
Current: 11.55
-18.65
11.91
ROC (Joel Greenblatt) (%) -272.12
GLPGF's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. GLPGF: -272.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -247.33  Med: -69.33 Max: 9.71
Current: -272.12
-247.33
9.71
Revenue Growth (3Y)(%) -14.10
GLPGF's Revenue Growth (3Y)(%) is ranked lower than
64% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GLPGF: -14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLPGF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -19.2  Med: 11.30 Max: 39.9
Current: -14.1
-19.2
39.9
EBITDA Growth (3Y)(%) 11.70
GLPGF's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. GLPGF: 11.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLPGF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.6  Med: 11.70 Max: 103.6
Current: 11.7
-45.6
103.6
EPS Growth (3Y)(%) 2.80
GLPGF's EPS Growth (3Y)(%) is ranked higher than
62% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. GLPGF: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLPGF' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.5  Med: 10.50 Max: 168.4
Current: 2.8
-69.5
168.4
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 46.70
GLPGF's P/E(ttm) is ranked lower than
54% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. GLPGF: 46.70 )
Ranked among companies with meaningful P/E(ttm) only.
GLPGF' s 10-Year P/E(ttm) Range
Min: 12.55  Med: 20.41 Max: 47.59
Current: 46.7
12.55
47.59
P/B 7.56
GLPGF's P/B is ranked lower than
68% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GLPGF: 7.56 )
Ranked among companies with meaningful P/B only.
GLPGF' s 10-Year P/B Range
Min: 0.61  Med: 1.42 Max: 7.7
Current: 7.56
0.61
7.7
P/S 22.35
GLPGF's P/S is ranked lower than
65% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. GLPGF: 22.35 )
Ranked among companies with meaningful P/S only.
GLPGF' s 10-Year P/S Range
Min: 0.91  Med: 3.67 Max: 22.76
Current: 22.35
0.91
22.76
Current Ratio 3.54
GLPGF's Current Ratio is ranked lower than
57% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. GLPGF: 3.54 )
Ranked among companies with meaningful Current Ratio only.
GLPGF' s 10-Year Current Ratio Range
Min: 1.22  Med: 2.60 Max: 3.54
Current: 3.54
1.22
3.54
Quick Ratio 3.53
GLPGF's Quick Ratio is ranked lower than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GLPGF: 3.53 )
Ranked among companies with meaningful Quick Ratio only.
GLPGF' s 10-Year Quick Ratio Range
Min: 1.22  Med: 2.37 Max: 3.53
Current: 3.53
1.22
3.53
Days Inventory 1.91
GLPGF's Days Inventory is ranked higher than
95% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. GLPGF: 1.91 )
Ranked among companies with meaningful Days Inventory only.
GLPGF' s 10-Year Days Inventory Range
Min: 1  Med: 17.48 Max: 122.45
Current: 1.91
1
122.45

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -2.70
GLPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GLPGF: -2.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLPGF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.1  Med: 0.80 Max: 31.26
Current: -2.7
-3.1
31.26

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0JXZ.UK, GLPG.Netherlands, GXE.Germany, GLPG.Belgium, GXEA.Germany, GLPG.USA,
Galapagos NV was founded in 1999. It is an integrated drug discovery company with capabilities from target discovery to clinical proof of concept. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The Group's operations were located in Belgium, Croatia, France, Switzerland, The Netherlands and United Kingdom. The Group's R&D division is located in Belgium, Croatia, France and The Netherlands, with its service division operating in the remaining countries. Sales of goods consist of the sale of chemical compound libraries on a non-exclusive basis. The Group faces competition from contract research companies that may bring products and services to the market which are more competitive or affordable and which might hurt the position of the service operations.
» More Articles for GLPGF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD... Jul 15 2015
Galapagos raises €4.4 million through warrant exercises Jun 22 2015
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis... Jun 18 2015
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment Jun 10 2015
May 26, 2015 Galapagos receives transparency notices May 27 2015
Galapagos announces closing of NASDAQ IPO May 20 2015
May 19, 2015 Galapagos announces share capital increase May 20 2015
Galapagos announces full exercise of underwriters’ option to purchase additional shares May 18 2015
Galapagos announces size of global offering increased to $250 million May 12 2015
May 7, 2015 Johnson & Johnson Innovation – JJDC, Inc. indicate interest in $25 million worth of... May 07 2015
May 6, 2015 Galapagos announces launch of proposed global offering May 06 2015
BNP Paribas notify of 4.8% shareholding in Galapagos May 04 2015
Galapagos creates new warrant plan May 04 2015
April 15, 2015 Galapagos files registration statement in the United States for a proposed global... Apr 16 2015
April 14, 2015 Galapagos’ JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key... Apr 15 2015
Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members... Mar 30 2015
Publication of Annual Report 2014 and invitation to the Annual Shareholders’ Meeting to be held on... Mar 30 2015
March 6, 2015 Galapagos reports 2014 financial results View English version - Bekijk Nederlandse... Mar 26 2015
March 6, 2015 Galapagos to be included in Amsterdam Midcap Index View English version - Bekijk... Mar 26 2015
March 17, 2015 Galapagos regains rights to GLPG1690, announces end of alliance with Janssen View... Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK